Clinical trial
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone…
NCT00134680 · Duke University, Other · Completed
Key facts
| NCT number | NCT00134680 |
|---|---|
| Title | Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC |
| Official title | Phase II Trial of the Combination of Letrozole 2.5 mg Daily and Trastuzumab 2 mg/kg Weekly in ErbB2 Positive and Estrogen Receptor and/or Progesterone Receptor Positive Metastatic Breast Cancer |
| Lead sponsor | Duke University, Other |
| Collaborators | Genentech, Inc. Industry Novartis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Letrozole, Trastuzumab |
| Enrollment | 33 |
| Start date | Jan 1, 2000 |
| Primary completion | Jan 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Aug 25, 2005 |
| Last update posted | Sep 16, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: